Sanofi will seek to draw from its experience with other drugs that treat rare blood disorders as it launches Enjaymo (sutimlimab-jome) as the sole drug approved to treat cold agglutinin disease (CAD), and the latest in the company’s efforts to build a rare blood disease franchise.
Enjaymo received US Food and Drug Administration approval on 4 February to decrease the need for red blood cell transfusion...







